Cellphire Therapeutics, Inc. news
Cellphire Therapeutics, Inc., a biotechnology company developing next-generation allogeneic cellular therapeutics for application across multiple medical indications, announced today the appointment of Roy A. Beveridge, M.D. to the company’s Scientific Advisory Board.
“Roy is a great addition to our Scientific Advisory Board,” said Mike Gaffney, Chief Executive Officer. “His depth of experience and deep insights will help steer us though our next phase of devel
Cellphire Therapeutics, Inc., a clinical stage biotechnology company developing next-generation allogeneic cellular therapeutics announced today the appointment of W. Allan Alexander, MD as the company’s Chief Medical Officer, effective immediately.
“Allan joining the team is an important milestone for Cellphire,” said Mike Gaffney, Chief Executive Officer. “His deep experience as both a practicing clinician and clinical developer in the hemostatic space will a
Cellphire Therapeutics, Inc., a biotechnology company developing next-generation allogeneic cellular therapeutics for application across multiple medical indications, announced today the appointment of Pamela B. Conley, Ph.D. to the company’s Board of Directors.
“Pam is a terrific addition to our Board,” said Mike Gaffney, Chief Executive Officer. “Her work leading the science, translational and clinical development work for Andexxa®, an antidote for blood
Cellphire Therapeutics, Inc., a biotechnology company developing next-generation allogeneic cellular therapeutics for application across multiple medical indications, announced today that Angie Howerton, CPA, has joined the company as Vice President of Finance, Controller and Treasurer, effective immediately. Ms. Howerton is an experienced finance professional with a continuous improvement mindset.
“We’re very pleased to have Angie join the Cellphire team,” sai
Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that the first patient has been dosed in the company’s Phase 2 dose-ranging study of Thrombosomes®, a platelet-based freeze-dried hemostatic agent, in bleeding patients with thrombocytopenia. The study will evaluate the safety and efficacy of infusing multiple dose levels of Thrombosomes versus st